Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Arcutis Biotherapeutics Inc.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Arcutis Biotherapeutics (ARQT – Research Report) a...

Analysts Conflicted on These Healthcare Names: Arcutis Biotherapeutics (ARQT) and Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT – Research Report) and Arcutis Biother...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ARQT	$25.57	+0.79%	1.44M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ARQT	$25.57	+0.8%	1.44M
3
4
5
6

ARQT

ARQT

Get Arcutis Biotherapeutics Inc. Data in Excel

Get Arcutis Biotherapeutics Inc. Data in Excel